All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Frontline Zanubrutinib Plus Rituximab Followed by Short-Course R-DHAOx Generates Preliminary Efficacy in MCL

January 15th 2023

First-line treatment with zanubrutinib plus rituximab followed by short-course rituximab plus dexamethasone, high-dose cytarabine, and oxaliplatin elicited responses in patients with mantle cell lymphoma, according to preliminary results from the phase 2 CHESS trial.

AFM24 Plus Atezolizumab Shows Acceptable Safety, Early Activity in EGFR+ Solid Tumors

January 14th 2023

A doublet comprised of the bispecific innate cell engager AFM24 and atezolizumab had a tolerable safety profile and elicited responses in patients with advanced EGFR-expressing solid tumors.

Teclistamab Plus Daratumumab/Lenalidomide Generates Responses in Relapsed/Refractory Myeloma

January 13th 2023

Emma Searle, PhD, provides an overview of findings from the MajesTEC-2 trial in patients with relapsed/refractory multiple myeloma, elaborates on the safety of teclistamab plus daratumumab and lenalidomide, and discusses the next steps for evaluating the combination.

Lutathera Improves PFS in Progressive Neuroendocrine Pancreatic Tumors

January 13th 2023

The use of peptide receptor radionuclide therapy with lutetium Lu 177 dotatate improved progression-free survival in patients with unresectable, progressive neuroendocrine pancreatic tumors.

Iyer Shares Ongoing Research in TSC1/2-Mutant Genitourinary Cancers

January 13th 2023

Gopa Iyer, MD, explained the rarity of TSC1 and TSC2 mutations in GU cancers, discussed the rationale and design of PRECISION 1, and emphasized the important role next-generation sequencing plays when determining the most effective targeted therapies for patients with GU cancers and other tumor types.

Fox Chase Cancer Center Welcomes Dr. Lindsey B. Taylor

January 13th 2023

Fox Chase Cancer Center is pleased to announce the hiring of Lindsey B. Taylor, MD, as an assistant professor in the Department of Hematology/Oncology and the Breast Cancer and Hematology Programs.

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

January 13th 2023

Moxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.

Treatment Paradigm of Advanced HCC Displays Exciting Growth in the First and Later Lines

January 13th 2023

Leading experts in the field of liver cancer contextualized how recent data are influencing the treatment paradigm in hepatocellular carcinoma.

Brexu-cel Elicits Durable Responses in High-Risk Relapsed/Refractory MCL

January 13th 2023

Treatment with brexucabtagene autoleucel produced ongoing responses in patients with mantle cell lymphoma with high-risk disease characteristics, including those with a lower ECOG performance score and tumor burden and less frequent prior use of bridging or platinum therapy.

ADXS-504 Study Increases Enrollment After Confirming Safety in Recurrent Early Prostate Cancer

January 12th 2023

ADXS-504, an investigational off-the-shelf neoantigen therapy, has been reported to be well tolerated and safe in patients with biochemically recurrent early prostate cancer.

CDX-1140 Plus Pembrolizumab Elicits Responses in PD-1/PD-L1–Resistant Solid Tumors

January 12th 2023

The utilization of the anti-CD40 agonist, CDX-1140, in combination with pembrolizumab was generally well tolerated and demonstrated preliminary efficacy in patients with anti–PD-1/PD-L1 resistant, locally advanced or metastatic solid tumors.

Older Patients of Color With Cancer Less Likely to Receive Opioids at End of Life

January 12th 2023

Results from a study of 318,549 Medicare beneficiaries with poor-prognosis cancers showed than Black and Hispanic patients were substantially less likely to receive any opioids or long-acting opioids than White patients at the end of life.

Florida Cancer Specialists & Research Institute Announces Pharmacy Leadership Appointments

January 12th 2023

Long-serving pharmacy executive, Ray Bailey, retired on December 31, 2022.

FDA Grants Orphan Drug Designation to QN-302 for Pancreatic Cancer

January 12th 2023

The FDA has granted an orphan drug designation to QN-302 for the treatment of patients with pancreatic cancer.

The Potential Clinical Utility of Cross-Trial Comparisons: An Example From Gynecologic Cancer Literature

January 12th 2023

because of the differences between the characteristics of research subjects and individuals routinely cared for outside the confines of a clinical trial, appropriately designed examinations of “real-world” populations may provide a more relevant picture of the actual influence of a particular therapeutic intervention.

Chari Spotlights Efficacy of Talquetamab and Next Steps for Exploration in R/R Multiple Myeloma

January 12th 2023

Ajai Chari, MD, shares some background on talquetamab, reported safety and efficacy findings from MonumenTAL-1, and highlighted other ways in which the agent is being explored in multiple myeloma.

BXCL701 Plus Pembrolizumab Generates Promising Responses in Small Cell Neuroendocrine mCRPC

January 11th 2023

The combination of BXCL701 and pembrolizumab produced encouraging responses in patients with small cell neuroendocrine carcinoma metastatic castration-resistant prostate cancer, according to topline data from a phase 2 trial.

Spira Highlights Key Advancements Across the NSCLC Treatment Paradigm in 2022

January 11th 2023

Alexander Spira, MD, PhD, FACP, highlights the top advancements across non–small cell lung cancer in 2022, emphasized the need for increased genetic testing to inform treatment decisions, and previewed other agents under development.

Study Reveals How Chronic Blood Cancer Transitions to Aggressive Disease

January 11th 2023

A type of chronic leukemia can simmer for many years and for a small percentage of patients, the slower paced disease can transform into an aggressive cancer, called secondary acute myeloid leukemia, that has few effective treatment options.

Mobocertinib Garners Approval in China for EGFR Exon 20 Insertion+ NSCLC

January 11th 2023

The National Medical Products Administration of China has approved mobocertinib for the treatment of adult patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations and whose disease progressed on or following platinum-based chemotherapy.